Loading...

We've got a brand new version of Simply Wall St! Try it out

XORTX Therapeutics

CNSX:XRX
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XRX
CNSX
CA$16M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
XRX Share Price and Events
7 Day Returns
138.1%
CNSX:XRX
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
31.6%
CNSX:XRX
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
XRX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
XORTX Therapeutics (XRX) 138.1% 108.3% 31.6% 31.6% - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • XRX outperformed the Pharmaceuticals industry which returned -45.8% over the past year.
  • XRX outperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

XRX Value

 Is XORTX Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for XORTX Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is CA$0.25.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for XORTX Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are XORTX Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:XRX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.01
CNSX:XRX Share Price ** CNSX (2019-09-19) in CAD CA$0.25
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of XORTX Therapeutics.

CNSX:XRX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:XRX Share Price ÷ EPS (both in CAD)

= 0.25 ÷ -0.01

-20.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XORTX Therapeutics is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • XORTX Therapeutics is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does XORTX Therapeutics's expected growth come at a high price?
Raw Data
CNSX:XRX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for XORTX Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on XORTX Therapeutics's assets?
Raw Data
CNSX:XRX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.00
CNSX:XRX Share Price * CNSX (2019-09-19) in CAD CA$0.25
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:XRX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:XRX Share Price ÷ Book Value per Share (both in CAD)

= 0.25 ÷ 0.00

764.53x

* Primary Listing of XORTX Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XORTX Therapeutics is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess XORTX Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. XORTX Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

XRX Future Performance

 How is XORTX Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XORTX Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is XORTX Therapeutics expected to grow at an attractive rate?
  • Unable to compare XORTX Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare XORTX Therapeutics's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare XORTX Therapeutics's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:XRX Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:XRX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:XRX Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -1
2019-03-31 -1 -1
2018-12-31 -2 -4
2018-09-30 -1 -4
2018-06-30 -1 -4
2018-03-31 -1 -3
2017-12-31 0 0
2017-09-30 0 0
2017-06-30 0 0
2017-03-31 0 0
2016-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if XORTX Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if XORTX Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:XRX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from XORTX Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:XRX Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 -0.06
2018-09-30 -0.08
2018-06-30 -0.09
2018-03-31 -0.11
2017-12-31 -0.02
2017-09-30 -0.02
2017-06-30 -0.02
2017-03-31 -0.02
2016-12-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if XORTX Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of XRX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. XORTX Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. XORTX Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess XORTX Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
XORTX Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

XRX Past Performance

  How has XORTX Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare XORTX Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • XORTX Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare XORTX Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare XORTX Therapeutics's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
XORTX Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from XORTX Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:XRX Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -0.76 0.41 0.19
2019-03-31 -0.88 0.45 0.30
2018-12-31 -3.78 0.73 0.34
2018-09-30 -3.88 0.80 0.39
2018-06-30 -3.66 0.74 0.25
2018-03-31 -3.45 0.67 0.13
2017-12-31 -0.47 0.36 0.07
2017-09-30 -0.40 0.36
2017-06-30 -0.47 0.44
2017-03-31 -0.44 0.41
2016-12-31 -0.41 0.39
2015-12-31 -0.28 0.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if XORTX Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if XORTX Therapeutics has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if XORTX Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess XORTX Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
XORTX Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

XRX Health

 How is XORTX Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up XORTX Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • XORTX Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • XORTX Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of XORTX Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 17.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from XORTX Therapeutics Company Filings, last reported 2 months ago.

CNSX:XRX Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 0.02 0.05 0.10
2019-03-31 0.16 0.05 0.14
2018-12-31 0.32 0.04 0.26
2018-09-30 0.46 0.04 0.39
2018-06-30 0.75 0.04 0.60
2018-03-31 1.00 0.04 0.87
2017-12-31 -0.65 0.27 0.06
2017-09-30 -0.43 0.23 0.10
2017-06-30 -0.39 0.13 0.01
2017-03-31 -0.32 0.12 0.02
2016-12-31 -0.32 0.12 0.02
2015-12-31 -0.12 0.00 0.03
  • XORTX Therapeutics's level of debt (227.9%) compared to net worth is high (greater than 40%).
  • Unable to establish if XORTX Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • XORTX Therapeutics has less than a year of cash runway based on current free cash flow.
  • XORTX Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 76.3% each year.
X
Financial health checks
We assess XORTX Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. XORTX Therapeutics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

XRX Dividends

 What is XORTX Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from XORTX Therapeutics dividends.
If you bought CA$2,000 of XORTX Therapeutics shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate XORTX Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate XORTX Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:XRX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as XORTX Therapeutics has not reported any payouts.
  • Unable to verify if XORTX Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of XORTX Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as XORTX Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess XORTX Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can XORTX Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. XORTX Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

XRX Management

 What is the CEO of XORTX Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Allen Davidoff
COMPENSATION CA$264,867
TENURE AS CEO 1.7 years
CEO Bio

Dr. Allen W. Davidoff, Ph.D. is founder and has been its Chief Executive Officer and President at XORTX Pharma Corp. , since January 9, 2018. Mr. Davidoff served as the Chief Scientific Officer of Stem Cell Therapeutics Corp. from December 31, 2010 to March 2012 and also served as its Vice President of Product Development from December 2004 to December 31, 2010. From September 2003 to December 2004, Mr. Davidoff served as Senior Clinical Scientist of Cardiome Pharma Corp. From September 2002 to March 2003, Dr. Davidoff served as Biotechnology Analyst for Lightyear Capital Inc., an investment dealer. His overall experience includes over 10 years of drug development experience with broad clinical and regulatory leadership experience. His senior management experience in pharmaceutical R&D includes two investigational new drug (IND) applications or supplemental IND's, two phase I studies (four multi-country), seven phase II studies and one NDA. He serves as a Director of XORTX Pharma Corp. He serves as a Director of Patient Stem Cell Resource Inc. Dr. Davidoff served as Director of Neurogenesis.

CEO Compensation
  • Insufficient data for Allen to compare compensation growth.
  • Allen's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the XORTX Therapeutics management team in years:

1.7
Average Tenure
  • The average tenure for the XORTX Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Allen Davidoff

TITLE
Founder
COMPENSATION
CA$265K
TENURE
1.7 yrs

Jim Fairbairn

TITLE
Chief Financial Officer
COMPENSATION
CA$25K
AGE
56
TENURE
0.8 yrs

Alan Moore

TITLE
Executive Consultant of Clinical & Regulatory Affairs
AGE
71
TENURE
1.7 yrs

Charlotte May

TITLE
Corporate Secretary
Board of Directors Tenure

Average tenure of the XORTX Therapeutics board of directors in years:

1.3
Average Tenure
  • The average tenure for the XORTX Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

W. Rowlands

TITLE
Chairman
COMPENSATION
CA$22K
TENURE
1.3 yrs

Allen Davidoff

TITLE
Founder
COMPENSATION
CA$265K
TENURE
1.7 yrs

Paul Van Damme

TITLE
Director
COMPENSATION
CA$22K
TENURE
1.7 yrs

Richard Johnson

TITLE
Member of Scientific Advisory Board

Henk ter Keurs

TITLE
Member of Scientific Advisory Board

Al Williams

TITLE
Director
COMPENSATION
CA$22K
AGE
61
TENURE
1.7 yrs

Petter Bjornstad

TITLE
Member of Clinical Advisory Board
TENURE
0.9 yrs

Fred Maese

TITLE
Member of Clinical Advisory Board
TENURE
0.9 yrs

Bruce Cousins

TITLE
Director
AGE
58
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by XORTX Therapeutics individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
05. Sep 19 Buy Allen Davidoff Individual 22. Aug 19 22. Aug 19 5,000 CA$0.14 CA$700
10. Jun 19 Buy Allen Davidoff Individual 06. Jun 19 06. Jun 19 5,000 CA$0.19 CA$950
16. Aug 19 Buy Allen Davidoff Individual 13. Aug 19 13. Aug 19 5,000 CA$0.17 CA$850
18. Jun 19 Buy Allen Davidoff Individual 13. Jun 19 13. Jun 19 5,000 CA$0.19 CA$950
27. May 19 Buy Allan Williams Individual 23. May 19 23. May 19 17,500 CA$0.20 CA$3,400
21. Feb 19 Buy W. Rowlands Individual 21. Feb 19 21. Feb 19 10,000 CA$0.21 CA$2,100
19. Feb 19 Buy W. Rowlands Individual 14. Feb 19 15. Feb 19 19,000 CA$0.24 CA$4,356
13. Feb 19 Buy W. Rowlands Individual 12. Feb 19 12. Feb 19 14,000 CA$0.22 CA$2,980
08. Feb 19 Buy W. Rowlands Individual 06. Feb 19 06. Feb 19 20,000 CA$0.20 CA$3,975
05. Feb 19 Buy W. Rowlands Individual 01. Feb 19 01. Feb 19 35,000 CA$0.18 CA$6,225
30. Jan 19 Buy Allen Davidoff Individual 22. Jan 19 22. Jan 19 1,000 CA$0.18 CA$175
30. Jan 19 Buy W. Rowlands Individual 30. Jan 19 30. Jan 19 9,000 CA$0.18 CA$1,620
28. Jan 19 Buy W. Rowlands Individual 24. Jan 19 25. Jan 19 28,500 CA$0.17 CA$4,695
17. Jan 19 Buy W. Rowlands Individual 04. Jan 19 16. Jan 19 29,000 CA$0.17 CA$4,621
17. Jan 19 Buy James Fairbairn Individual 16. Jan 19 16. Jan 19 10,000 CA$0.16 CA$1,600
16. Jan 19 Buy W. Rowlands Individual 10. Jan 19 15. Jan 19 35,500 CA$0.15 CA$5,329
11. Jan 19 Buy W. Rowlands Individual 07. Jan 19 08. Jan 19 26,000 CA$0.18 CA$3,889
23. Jan 19 Buy W. Rowlands Individual 22. Jan 19 22. Jan 19 1,000 CA$0.16 CA$160
22. Jan 19 Buy W. Rowlands Individual 21. Jan 19 22. Jan 19 20,000 CA$0.17 CA$3,258
04. Jan 19 Buy Allen Davidoff Individual 28. Dec 18 03. Jan 19 2,000 CA$0.19 CA$363
19. Nov 18 Buy W. Rowlands Individual 13. Nov 18 16. Nov 18 30,000 CA$0.21 CA$5,992
X
Management checks
We assess XORTX Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. XORTX Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

XRX News

Simply Wall St News

Did You Manage To Avoid XORTX Therapeutics's (CNSX:XRX) 15% Share Price Drop?

It seems likely some shareholders believe that XORTX Therapeutics will significantly advance the business plan before too long. … But with the share price diving 15% in the last year, it's probably fair to say that some shareholders no longer believe the company will succeed. … A Different Perspective While XORTX Therapeutics shareholders are down 15% for the year, the market itself is up 1.1%.

Simply Wall St -

What Kind Of Shareholders Own XORTX Therapeutics Inc. (CNSX:XRX)?

Generally speaking, as a company grows, institutions will increase their ownership. … XORTX Therapeutics is a smaller company with a market capitalization of CA$11m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Breaking Down XORTX Therapeutics Inc's (CNSX:XRX) Ownership Structure

I am going to take a deep dive into XORTX Therapeutics Inc’s (CNSX:XRX) most recent ownership structure, not a frequent subject of discussion among individual investors. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … CNSX:XRX Ownership Summary August 22nd 18

Simply Wall St -

XRX Company Info

Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. It has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. The company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. In addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. The company has strategic alliance with Teijin Pharma Limited to develop TMX-049, a xanthine oxidoreductase. XORTX Therapeutics Inc. is headquartered in Calgary, Canada.

Details
Name: XORTX Therapeutics Inc.
XRX
Exchange: CNSX
Founded:
CA$15,729,922
62,919,691
Website: http://www.xortx.com
Address: XORTX Therapeutics Inc.
421 7th Avenue SW,
Suite 4000,
Calgary,
Alberta, T2P 4K9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX XRX Class A Common Shares Canadian National Stock Exchange CA CAD 11. Jan 2018
OTCPK XRTX.F Class A Common Shares Pink Sheets LLC US USD 11. Jan 2018
DB ANU1 Class A Common Shares Deutsche Boerse AG DE EUR 11. Jan 2018
Number of employees
Current staff
Staff numbers
0
XORTX Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:25
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.